a manufacturer of plasma-derived biological medicines
Industry PharmaceuticalsMajor
A.I.dvisor detected a bullish Head-and-Shoulders Bottom pattern for GRFS stock. This pattern was detected on June 17, 2026 . The odds of reaching the target price are 6.
The Head-and-Shoulders Bottom pattern is formed when the price of a security creates a center trough (the inverted head, labeled 3) and the left and right inverted shoulders (1, 5). After reaching the lowest low (the Head, 3) the next low is shallower and the trend reverses course to the upside.
Consider buying a security or a call option at the low once the pattern is confirmed, which is known as the breakout point. The pattern is confirmed when the price breaks above the Neckline (2,4).
The Moving Average Convergence Divergence (MACD) for GRFS turned positive on July 02, 2026. Looking at past instances where GRFS's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on July 07, 2026. You may want to consider a long position or call options on GRFS as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GRFS advanced for three days, in of 270 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GRFS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for GRFS entered a downward trend on July 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.788) is normal, around the industry mean (19.687). P/E Ratio (10.380) is within average values for comparable stocks, (27.924). Projected Growth (PEG Ratio) (0.189) is also within normal values, averaging (3.924). Dividend Yield (0.039) settles around the average of (0.031) among similar stocks. GRFS's P/S Ratio (0.579) is slightly lower than the industry average of (4.184).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. GRFS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GRFS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock worse than average.